Seres Therapeutics, Inc. (NASDAQ:MCRB)‘s stock had its “buy” rating reiterated by Cowen and Company in a note issued to investors on Monday.

The analysts wrote, “Seres reported top-line results from a Phase 1b trial of SER-287 in 58 patients with.””

Several other equities analysts have also weighed in on the stock. ValuEngine lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. HC Wainwright restated a “buy” rating and set a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Canaccord Genuity set a $20.00 price objective on shares of Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Friday, July 14th. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Wednesday, August 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $17.00.

Seres Therapeutics (NASDAQ MCRB) opened at 12.64 on Monday. Seres Therapeutics has a 12-month low of $8.86 and a 12-month high of $17.42. The firm’s market capitalization is $512.07 million. The firm has a 50 day moving average of $15.27 and a 200 day moving average of $15.27.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.10). The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.70) earnings per share. On average, analysts forecast that Seres Therapeutics will post ($2.48) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Cowen and Company Reiterates “Buy” Rating for Seres Therapeutics, Inc. (MCRB)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/cowen-and-company-reiterates-buy-rating-for-seres-therapeutics-inc-mcrb/1607502.html.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Seres Therapeutics by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock worth $17,911,000 after acquiring an additional 19,363 shares during the period. ARK Investment Management LLC increased its holdings in Seres Therapeutics by 21.5% in the 2nd quarter. ARK Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock worth $8,647,000 after acquiring an additional 135,276 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Seres Therapeutics by 15.9% in the 1st quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after acquiring an additional 50,860 shares during the period. State Street Corp raised its stake in Seres Therapeutics by 12.0% in the 2nd quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after acquiring an additional 34,393 shares during the period. Finally, Northern Trust Corp raised its stake in Seres Therapeutics by 16.2% in the 2nd quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after acquiring an additional 32,875 shares during the period. Institutional investors own 74.76% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.